Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Always great posts by Dr. Jerry...
Thanks
The CEO is Canadian
Orphan drug development has several advantages:
It takes just under 5 years from Phase 2 clinical trial to market, as opposed to 6 to 8 years for traditional drug approval
Orphan designations have better odds for approval with an 82% success rate (Phase 2 forward) as opposed to 35% for traditional drugs
Orphan products have attractive profitability given the smaller patient populations, which drive premium pricing and lower cost of sales
Orphan products experience ongoing revenue growth due to steady uptake after launch with chronic, lifetime customers
Orphan products experience significant competitive advantage to being first to market
He will tell the Medical world, about how many different indications this potential Blockbuster Drug can help treat or cure.
we have only heard a few.. I believe there are more to come.
Vegas.. you are wrong about Dr. Rubinfeld though
He has not said this about every company he backs...
"in my 45 year career in the bio-pharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen"
i don't think you need to try to discredit the good Dr.
and remember there are Advisors from Bayer & Bristol Myers Squibb who say the same thing as Dr. Rubinfeld.
Dr. Rubinsfeld's Opinion carries more weight in the Medical world than yours does if he says Kool Aid can be a cure for something they would listen to him.. while if you said it they would laugh.
but it is an IF I agree with that... but they have various experts in the field saying it can possibly work. and other similar technologies have gotten funded with the same IF........to me the Patent challenge was the eye opener.
Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinson's Disease
http://www.prnewswire.com/news-releases/amarantus-biosciences-announces-positive-data-for-manf-in-delivery-diffusion-animal-model-of-parkinsons-disease-180974311.html
a blockbuster drug $AMBS$
Dr. Rubinfeld will assist management in positioning the Company’s development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.
“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson’s, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company’s new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.”
Enough Said... Goodnight
Parkinson's Disease Market at $20 Billion
Heart Treatment Market $45 Billion
T.B.I Market $10 Billion
And thats just a few of the markets they will focus on ... its truly unlimited .
You do the math..
$AMBS$
Here are the Scientific Publications on
MANF
these are on the website.. Most Important part... AMBS has the PATENTS
Oh-Hashi K, Tanaka K, Koga H, Hirata Y, Kiuchi K (2012). Intracellular trafficking and secretion of mouse mesencephalic astrocyte-derived neurotrophic factor. Mol Cell Biochem. 363: 35-41.
Niles LP, Sathiyapalan A, Bahna S, Kang NH, Pan Y. (2011) Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain. Int J Neuropsychopharmacol 16: 1-8.
Hellman U, Arumäe U, Yu L, Lindholm P, Peränen J, Saarma M, Permi P (2011) Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons . J Biol Chem 286:2675-2680.
Voutilainen MH, Bäck S, Peränen J, Lindholm P, Raasmaja A, Männistö PT, Saarma M, Tuominen RK. (2011) Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson’s disease. Exp Neurol. 228: 99-108.
Glembotski CC (2010) Functions for the cardiomyokine, MANF, in cardioprotection, hypertrophy and heart failure. J Mol Cell Cardiology, In Press
Hellman U, Peränen J, Saarma M, Permpanich B (2010) (1)H, (13)C and (15)N resonance assignments of the human mesencephalic astrocyte-derived neurotrophic factor. Biomol NMR Assign 4:215-217.
Airavaara M, Chiocco MJ, Howard DB, Zuchowski KL, Peränen J, Liu C, Fang S, Hoffer BJ, Wang Y, Harvey CA (2010) Widespread cortical expression of MANF by AAV serotype 7: Localization and protection against ischemic brain injury. Exp Neurol 225:104-113.
Lindholm P, Saarma M (2010) Novel CDNF/MANF Family of Neurotrophic Factors. Dev Neurobiol 70:360-371.
Voutilainen M, Back S, Porsti E., Toppinen L, Lindgren L, Lindholm P, Peranen J, Saarma M and Tuominen R (2009). Mesencephalic Astrocyte-derived Neurotrophic Factor is Neurorestorative in a Rat Model of Parkinson’s Disease. J Neurosci, July 29, 2009. 29(30):9651–9659.
Yong-Qiang Yu1, Lian-Cheng Liu1, Fa-Cai Wang2, Yan Liang2, Da-Qin Cha2, Jing-Jing Zhang2, Yu-Jun Shen2, Hai-Ping Wang2, Shengyun Fang2,3 and Yu-Xian Shen2 (2009). Induction profile of MANF/ARMET by cerebral ischemia and its implication for neuron protection, J CBFM Sept 23: 1–13
Airavaara M, Shen H, Kuo C-C, Peränen J, Saarma M, Hoffer B, Wang Y (2009) Mesencephalic astrocyte-derived neurotrophic factor reduces ischemic brain injury and promotes behavioral recovery in rats. J Comp Neurol 515: 116-124.
Parkash V, Lindholm P, Peranen J, Kalkkinen N, Oksanen E, Saarma M, Leppanen VM, Goldman A (2009). The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Engineering Design Selection 22: 233-24.
Palgia M, Lindstrom R, Peranen J, T. Piepponen P, Saarma M, Tapio I. Heino TI (2009) Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. PNAS 106: 2429–2434.
Tadimalla A, Belmont PJ, Thuerauf DJ, Glassy MS, Martindale JJ, Gude N, Sussman MA, Glembotski CC (2008) Mesencephalic Astrocyte-Derived Neurotrophic Factor Is an Ischemia-Inducible Secreted Endoplasmic Reticulum Stress Response Protein in the Heart. Cir Res 103: 1249-1258.
Lindholm P, Andressoo J-O, Kalkkinen N, Kokaia Z, Lindvall O, Timmusk T, Peranen J, Saarma M (2008). MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain. Mol Cell Neurosci 39: 356-371
Apostolou A, Shen Y, Liang Y, Lou Y, Fang S. (2008) Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp Cell Res 14: 2454-2467.
Mizobuchi N, Hoseki J, Kubota H, Toyokuni Y, Nozaki K, Naitoh M, Koizumi A, Nagata K. (2007) ARMET is a Soluble ER Protein Induced by the Unfolded Protein Response via ERSE-II Element. Cell Struct Funct 32: 41-50.
Zhou C, Xiao C, Commissiong JW, Krnjevic K, Ye JH. (2006) Mesencephalic astrocyte-derived neurotrophic factor enhances nigral [gamma]-aminobutyric acid release. NeuroReport 17: 293-297.
Petrova PS, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire A, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW. (2004) Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases. Prog Brain Res 146: 168-183.
Petrova PS, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire AE, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW. (2003) MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 20: 173-188.
PhenoGuard Protein Discovery Engine
Takeshima T, Johnston JM, Commissiong JW (1994) Mesencephalic type-1 astrocytes rescue dopaminergic neurons from death induced by derum-deprivation. J Neurosci 14: 4769-4779
Panchision D., Martin-DeLeon P, Takeshima T, Johnston J, Shimoda K, Tsoulfas P, McKay R, Commissiong JW (1998). An immortalized Type-1 Astrocyte Origin of a Dopaminergic Neurotrophic Factor. J Mol Neurosci. 11-208-221
Takeshima T., Shimoda K. Johnston J.M., Commissiong J. (1996). Standard methods to bioassay neurotrophic factors for dopaminergic neurons. J Neurosci Meth 67: 27-41
its in the news of AMBS and on the this site as well
http://www.rainbowbiosciences.com/news.html
Deal looks like its in place just waiting for the timing,.. they will help them with the initial revenue project for the commercialization of the diagnostic test. NuroPro
Gerald knows CEO of RBCC well from Stanford... Ceo Patrick Brown is a professor of biochemistry at Stanford
the MANF development is where they will get BIG PHARMA involved since it will have so many avenues to go through.
this is all my opinion and my best guesses are in here too..
DUCKS IN A ROW DUCKS IN A ROW .. $ AMBS $
THEY HAVE THEM IN A ROW WHO HAS NOT NOTICED THIS YET?
Rainbow BioSciences has signed a Letter of Intent (LOI) with an emerging industry powerhouse, Amarantus Biosciences, Inc.
Once a definitive deal is signed, the two companies will be positioned to bring a proprietary new Parkinson's treatment to the market, and possibly, cure the disease.
this is still in the works..... would not be surprised if this deal being closed.... is announced after Showcase
I like that peers already call them a POWERHOUSE...
Desperate for shares. Makes investors do anything, To try to beat a winner down. They are losing this fight. AMBS wins
AMBS. Has solid advisors who have seen it all and with major contacts in the pharmaceutical world.
The auction to the highest bidder is on the 9th don't forget that.
Cure for Parkinson's Disease. $AMBS$.
And many other possible medical breakthroughs.
This is what this is about.
Don't let scare tactics deny your Success
Im Buying heavily today if the weak handed allow me to.
Legendary once in a blue moon opportunity here.
Don't let the scare tactics deter you from success.
A CURE For Parkinson's Disease !!!!
And many more possibilities.
You have to silly to sell or not purchase now.
Don't let Fear get in the way of your success.
Your F is worth $250 Million My F is worth $350 Million
Im 36% better than you..
but this in not an "F" this is a straight A and you know it..
MANF performed 36% Better than GDNF
so your previous statement is wrong and misleading.
Have a nice night
Adding everyday. Legendary.
These stock opportunities are talked about for years to come.
Don't let fear deter you from succeeding
Legendary. $AMBS$
No matter how hard they try.
Can't keep AMBS down
Already up on my latest addition
This is legendary
Added a ton of shares. Thanks for shaking out the weak. Such a manipulated swing. So obvious.
TD my account has same error, Pretty sure it will update after close.
Yes TD waterhouse
TD added my shares this AM
Plus picked up more at the Dip.
Very good post.
AMBS $$$$$
AMBS Biotech Showcase 2013 Small Tidbit of Information:
I didn't count the exact number but aprox. 170 companies are presenting at the Showcase
there are 3 types of meeting rooms to give the presentations
30 of the companies are presenting in the larger of the meeting rooms. one of those 30 is: AMBS
now the rooms are not to big to begin with... but they were given or requested the 1100 Square foot room instead of the 700 Sq Foot
this may mean something or nothing but i thought of passing it along.
i think it means they are expecting a bigger turnout
i like to cover all angles
GL2ALL AMBS $$$$
I have bought with TD since Cusip change. Just cant move old shares yet. Which i wont anyways.
I like the US GOV. Angle
Dr. John Commissiong worked for the US Government on 2 occasions
its a possible scenario , but do you really think shorts are gonna sit and watch the price go up when they have to cover? this company knows what its doing... they timed all this perfectly. CUSIP change, positive announcements, Letters of Intent for marketing & TBI Awareness initiative ( possible NFL backing), pushing back Data result to conference to make a bigger impact in front of major VC and Big Pharma, Share Holder Rights.. they are doing this right step by step.
I think the shorts needing to cover are going to be more desperate, than shareholders wanting to sell
that is my opinion.
Excellent Post. Doc
your shares are there.... they are being swapped 1 for 1 with new shares with new CUSIP Number... should have the new ones in your account soon this happened on the 28th takes usually 3 or 4 days for the swap
he said they can't buy(Freudian slip) implying the news is good.. that's how i interpreted it.
but i pick up on those things.. thats just me
Yes Gerald replied yesterday to an Email i sent him on the 28th.
he is a little busy preparing for the conference but he did reply.
this is what he wrote:
"We will be updating the entire market regarding the share structure in the appropriate time. The most recent 10Q has the most up-to-date information available to the market. The Company maintains that it has not entered into any additional financing transactions since the last 10Q, the Company has not sold any shares and none of the officers or directors have sold any shares. Given the data that is upcoming, the officers and directors are precluded from buying shares in the marketplace at this time until the data is released, as that is material non-public information.
Best Regards,
Gerald"
400k shares at .13 in last Minute
nice..Photo finish..
AMBS!!
Regular Hours today..4pm close. just Bond market closes at 2:00pm
someone correct me if im wrong
when the NFL logo appears next to Amarantus...
you better buckle up your chin straps .. each team will have to invest in their TBI treatment research..